The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND:Complete response (CR) at the primary tumor site as assessed by clinical examination following induction chemotherapy with PF (cisplatin and 5‐fluorouracil [5‐FU]) is a favorable predictive factor for overall survival and disease control in patients with locally advanced squamous cell carcinoma of the head and neck. In most series, the rate of CR at the primary site after induction PF was...
BACKGROUND:Given the complexity of management of advanced head and neck squamous cell carcinoma (HNSCC), this study hypothesized that high hospital volume would be associated with receiving National Comprehensive Cancer Network (NCCN) guideline therapy and improved survival in patients with advanced HNSCC.
METHODS:The Surveillance, Epidemiology, and End Results (SEER)‐Medicare database was used to...
BACKGROUNDThe objective of this study was to evaluate the long‐term survival and late toxicities of concurrent‐adjuvant chemotherapy in patients with stage III through IVB nasopharyngeal carcinoma (NPC) from endemic regions of China.
METHODSPatients with stage III to IVB NPC were assigned randomly to receive radiotherapy (RT) alone (the RT group) or RT plus concurrent adjuvant chemotherapy (the CRT...
BACKGROUNDGerm cell tumors (GCTs) primarily affect adolescent and young adult men. Detailed clinical and treatment characteristics in older men are lacking.
METHODSPatients with GCT seen over a 20‐year period at Memorial Sloan‐Kettering Cancer Center were identified. Primary tumor site and histology were compared for patients aged ≥ 50 years at diagnosis versus younger men. For patients aged ≥ 50,...
BACKGROUNDUse of progression‐free survival (PFS) as a clinical trial endpoint in first‐line treatment of patients with metastatic urothelial carcinoma (UC) is attractive, but would be enhanced by establishing a correlation between PFS and overall survival (OS).
METHODSData was pooled from 7 phase 2 and 3 trials evaluating cisplatin‐based chemotherapy in metastatic UC. An independent cohort of patients...
BACKGROUNDThe current study was conducted to develop a pretreatment prognostic model for patients with unresectable and/or metastatic urothelial cancer who were treated with first‐line, cisplatin‐based chemotherapy.
METHODSIndividual data were pooled from 399 patients who were enrolled on 8 phase 2 and 3 trials evaluating cisplatin‐based, first‐line chemotherapy in patients with metastatic urothelial...
BACKGROUNDThis study sought to determine the feasibility and recommended phase 2 dose (RP2D) of the combination of cetuximab with chemoradiotherapy based on 5‐fluorouracil (5‐FU) and cisplatin (CP) in locally advanced anal canal carcinoma.
METHODSCetuximab was administered on days 1, 8, 15, 29, 36, 43, and 50 (400 mg/m2 initial dose, then 250 mg/m2/week) concurrent with total dose radiation of 55...
BACKGROUNDWeekly or daily cisplatin and 5‐fluorouracil (5‐FU)‐based chemoradiation was evaluated for patients with locally advanced squamous cell carcinoma (SCC) of the anal canal treated at a single institution over a 20‐year period.
METHODSA retrospective, single‐institution analysis was conducted of patients receiving concurrent 5‐FU/cisplatin and radiotherapy for locally advanced SCC from 1989...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.